Wall Street analysts have been active across a broad spectrum of the S&P 500, with 19 distinct price target adjustments recorded over the last two weeks as of June 28, 2026. The Financials sector stands out for a coordinated string of optimism from Truist Securities, which lifted price targets on six major banking institutions, including JPMorgan Chase, Citigroup, and Bank of America. While the mood in banking remains constructive, other sectors are experiencing more friction, particularly within Consumer Staples and Discretionary retail.
| Ticker | Firm | Dir | Prior → Current |
|---|---|---|---|
| DRI | UBS | Up | 230 → 240 |
| WFC | Truist | Up | 90 → 94 |
| NKE | Deutsche Bank | Down | 51 → 43 |
| ZTS | Stifel | Down | 95 → 85 |
| MSFT | Stifel | Down | 415 → 400 |
Revision log
The divergence in analyst sentiment is perhaps best illustrated by the activity surrounding McCormick & Company (MKC). It saw a curious tug-of-war, with UBS raising their target from $51 to $52, while TD Cowen and Bernstein both moved to lower their targets on the stock to $60 and $68, respectively. This split highlights the difficulty firms are having in pinning down value in the current climate.
Elsewhere, the volatility in the apparel space is sharp. Nike (NKE) faced significant pressure, with Deutsche Bank and Oppenheimer both slashing their price targets—the latter cutting their view from $120 all the way down to $60. This is a stark contrast to the moderate confidence seen in the financial sector moves. Meanwhile, in the technology space, Applied Materials (AMAT) received an uptick to $740 from Wells Fargo, and Accenture (ACN) saw a slight boost from TD Cowen.
Takeaways for readers
The recent volume of downward revisions in the Consumer Staples sector suggests that analysts are growing increasingly cautious about margin pressures for food and beverage giants. Companies like General Mills (GIS), PepsiCo (PEP), and Conagra (CAG) all saw their targets pared back, signaling a potential shift in earnings expectations for the coming quarters.
One detail to isolate is the aggressive stance taken on healthcare names. Stifel, in particular, lowered their targets for both Boston Scientific (BSX) and Zoetis (ZTS). Notably, the implied upside for BSX remains high at 69.6% despite the revision, which serves as a reminder that a target reduction does not necessarily imply a bearish outlook; it often reflects a recalibration of models against shifting market realities. These moves, when aggregated, provide a clear snapshot of how institutional analysts are adjusting their expectations heading into the next reporting cycle.